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Asymmetric trehalose analogues to probe
disaccharide processing pathways in
mycobacteria†
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The uptake and metabolism of the disaccharide trehalose by Mycobacterium tuberculosis is essential for
the virulence of this pathogen. Here we describe the chemoenzymatic synthesis of new azido-functiona-
lised asymmetric trehalose probes that resist degradation by mycobacterial enzymes and are used to
probe trehalose processing pathways in mycobacteria.
Introduction
Mycobacterium tuberculosis (Mtb), the causative agent of tuber-
culosis (TB), is a major global health challenge. TB is now the
leading cause of death from a single infectious agent world-
wide with 1.5 million deaths reported in 2018 alone, more
than HIV and malaria combined.1 The incidences of drug-
resistant strains of TB are escalating which increases the com-
plexity of effective treatment regimens and the implementation
of control measures. Therefore, there is an urgent need to
develop new interventions to combat this global pathogen.
One of the distinguishing features of Mtb is a highly
complex cell envelope that provides a very effective barrier
against many antibiotics and further complicates TB drug-regi-
mens, whilst lipid components of the cell envelope play impor-
tant roles in its pathogenicity.2–4 The Mtb cell wall core con-
sists of mycolic acids covalently linked to arabinogalactan that
is attached to peptidoglycan, known as the mAGP complex.4
Additional non-covalently linked lipids and lipoglycans inter-
calate within the lipid environment to form an outer ‘myco-
membrane’ and include the trehalose containing glycolipids,
trehalose mono- and dimycolates (TMM and TDM
respectively).3,5 TMM and TDM are essential components of
the mycobacterial cell envelope for both the viability and viru-
lence of the Mtb pathogen.3 It has recently been reported that
‘free’ trehalose released from these glycolipids through the
catalytic action of the antigen 85 (Ag85) complex, is reused
through uptake via the Mtb LpqY-SugABC transporter and this
recycling process is critical for virulence.6 Given that Mtb
resides within a nutrient poor environment this recycling strat-
egy provides a route for Mtb to scavenge an essential carbon
source that can subsequently be utilised as a key metabolite in
a number of biosynthetic processes.6–8 For these reasons, tar-
geting trehalose uptake and metabolism in Mtb has recently
gained attention as an attractive route for the development of
new anti-tubercular therapeutic and diagnostic agents.
To develop effective trehalose targeting strategies in myco-
bacteria chemical tools are required to increase our under-
standing of Mtb trehalose metabolism. Recent studies have
incorporated bioorthogonal handles and fluorescent moieties
into the trehalose scaffold with retention of the α,α1,1-glycosi-
dic bond and these probes have been used for live imaging
of mycobacteria and for the rapid detection of Mtb in
sputum.9–13 The diverse panel of unnatural trehalose-based
probes has been an important step towards providing insights
into the molecular pathways of trehalose metabolism in Mtb.
However, enzymes that are present in both Mtb and the
human host can metabolise trehalose which has the potential
to lead to a loss in the labelling efficacy and potential off-
target effects of the modified trehalose probes.14–17 In Mtb
there are two main pathways that metabolise trehalose. The
Mtb trehalase enzyme catalyses the hydrolysis of the α,α1,1-gly-
cosidic bond of trehalose to form two molecules of glucose
(Fig. 1).15 Alternatively, the Mtb trehalose synthase (TreS)
enzyme can isomerise trehalose through rearrangement of the
α,α1,1-linkage to form the α1,4-linked glucose disaccharide
maltose (Fig. 1).18 Therefore, there is a need for an alternative
approach and the identification of enzymatically-stable chemi-
cal probes that can still be utilised by the mycobacterial treha-
lose processing machinery. We therefore reasoned that asym-
metric trehalose analogues, in which one glucose moiety is
replaced with either mannose (mannotrehalose (2)) or galac-
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tose (galactotrehalose (3)) and the corresponding 6-azido
modified versions (5–6), are an appealing route to generate tre-
halose probes with improved metabolic profiles that are resist-
ant to degradation in mycobacteria (Scheme 1). Here, we
report the chemoenzymatic synthesis of asymmetric trehalose
derivatives and their evaluation as mycobacterial probes.
Results and discussion
To obtain mannotrehalose (2), galactotrehalose (3) and the
corresponding 6-azido-modified derivatives 5–6 a modified
chemoenzymatic method previously reported by Swarts et al.
was employed utilising the trehalose synthase (TreT) enzyme
from Thermoproteus tenax (Scheme 1).19 Enzymatic reactions
were performed at 70 °C for 2 h in 50 mM HEPES, 300 mM
NaCl, pH 8.0 and the equivalents of the glucose
analogue : UDP-glucose varied. The exact ratios and full che-
moenzymatic synthesis details are specified in the ESI
Methods.† Previous studies report that glucose analogues
modified at the 4-position are poor substrates of TreT.19 Here
we found that altering the ratio of galactose : UDP-glucose
from 1 : 4 to 1.5 : 1 improved the conversion of galactose to the
corresponding galactotrehalose analogue and increased the
yield of 3 from 12% to 28%. Employing this approach resulted
in the generation of trehalose analogues 2–6 in a single-step
from commercially available glucose analogues (Scheme 1).
The reaction products were readily purified by size-exclusion
chromatography and HPLC to obtain compounds 2–6, and the
purified products analysed by 1H and 13C NMR and mass spec-
trometry to confirm the formation of the correct structure and
retention of the α,α1,1-glycosidic bond (ESI Fig. S4–S13†).
These results expand on the known substrate profile tolerated
by TreT to include 6-azido-mannose and 6-azido-galactose
enabling access to unnatural azido-modified mannotrehalose
(5) and galactotrehalose (6) disaccharides respectively via a
chemoenzymatic route, thereby expanding the trehalose probe
toolkit.
Having chemoenzymatically synthesised mannotrehalose
(2), galactotrehalose (3) and the azido-derivatives (5–6) we eval-
uated whether the trehalose analogues were resistant to degra-
dation by the mycobacterial trehalase and TreS enzymes. We
first incubated 30 mM of either trehalose (1), trehalose ana-
logues 2–3 or azido-trehalose analogues (4–6) with the recom-
binant trehalase enzyme from Mycobacterium smegmatis, or
with buffer alone containing no enzyme, over 19 h and the
reaction products analysed by thin-layer chromatography (TLC)
(Fig. 2). As expected,15 within 1 h we observed the rapid cata-
lytic degradation of trehalose (1) to glucose by the
M. smegmatis trehalase enzyme (ESI Fig. S1A†). Further charac-
terisation revealed that azido-trehalose (4) is also a substrate of
the mycobacterial trehalase enzyme although the rate of hydro-
lysis of azido-trehalose (4) is lower than that observed for the
Fig. 1 Pathways involved in trehalose uptake and metabolism in myco-
bacteria. TMM: trehalose monomycolate.
Scheme 1 Chemoenzymatic synthesis of trehalose analogues.
Fig. 2 Activity of M. smegmatis trehalase with trehalose 1 and trehalose
derivatives (2–6). Compounds were incubated in the absence (−) or
presence (+) of the M. smegmatis trehalase enzyme for 19 h.
Mannotrehalose (2), galactotrehalose (3), azido-trehalose (4), azido-
mannotrehalose (5) and azido-galactotrehalose (6).
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endogenous trehalose substrate (ESI Fig. S1B†). These results
provide the first evidence that 6-azido-trehalose probes have
the potential to be degraded by mycobacterial enzymes
leading to the generation of glucose and azido-glucose mono-
saccharides that could be used as a substrate to regenerate
6-azido-trehalose or diverted into alternative, non-trehalose
specific processing pathways. Further experiments are required
to determine the importance of 6-azido-trehalose degradation
and the impact on metabolic labelling in mycobacteria. In con-
trast, only very low levels of hydrolysis of the epimeric treha-
lose analogues mannotrehalose (2), galactotrehalose (3) and
no hydrolysis of the corresponding azido-derivatives 5–6 were
observed under the same test conditions at the extended 19 h
time point (Fig. 2). Taken together these findings indicate that
the manno- and galacto-trehalose derivatives (2–3 and 5–6) are
poorly tolerated by the mycobacterial trehalase enzyme high-
lighting that stereochemical inversion of the 2- and 4-hydroxy
groups results in highly hydrolytically stable trehalose
analogues.
Next, we investigated whether the mycobacterial TreS
enzyme is able to isomerise the asymmetric trehalose ana-
logues 2–6. 20 mM of trehalose (1) or trehalose analogues 2–6
were incubated with the TreS enzyme from M. smegmatis and
the reaction monitored by TLC. In this instance, it was clearly
observed that trehalose was isomerised to maltose by TreS
after 30 min (ESI Fig. S2†), whereas we were unable to detect
any product from the TreS reaction under the same conditions
with either mannotrehalose 2, galactotrehalose 3 or the azido-
derivatives 4–6 over a 4.5 h period (Fig. 3). The reversible
isomerisation of trehalose by the mycobacterial TreS enzyme
proceeds via the formation of a glucosyl-TreS enzyme inter-
mediate followed by release and reorientation of glucose to
enable either the 1- or 4-hydroxy group to reattack to generate
either trehalose or maltose respectively.17 The absence of any
observed isomerisation of 2–3 and the azido-derivatives 4–6
coupled with the lack of glucose build up indicates that the
mycobacterial TreS enzyme is sensitive to the stereochemistry
of both halves of the molecule and that modification at the
6-position with an azido-group is not tolerated. These results
demonstrate the high stability of all trehalose analogues (2–6)
to isomerisation by the mycobacterial TreS.
Having demonstrated that mannotrehalose (2), galactotre-
halose (3) and the corresponding azido-analogues (5–6) are
hydrolytically stable to the mycobacterial trehalase and resist-
ant to isomerisation by the mycobacterial TreS enzyme we
evaluated whether the asymmetric trehalose analogues 2 and 3
support the growth of mycobacteria. M. smegmatis and
Mycobacterium bovis BCG were grown to mid-exponential
phase, starved overnight in PBS containing 0.05% tyloxapol
and then grown in defined minimal-media supplemented with
either 2.9 mM trehalose (1) or trehalose analogues 2 and 3 as
sole carbon sources (Fig. 4). In agreement with previous
studies,20 both M. smegmatis and M. bovis BCG were able to
grow in the presence of trehalose alone. Notably, in direct con-
trast, both mannotrehalose (2) and galactotrehalose (3) were
unable to support the growth of M. smegmatis or M. bovis BCG
(Fig. 4). Our metabolic labelling experiments (see later) indi-
cate that azido-analogues of 2 and 3 modified at the 6-position
(5–6) can be taken up by mycobacteria. These findings there-
fore support the notion that within a nutrient limited environ-
ment the degradation of trehalose is required to support myco-
bacterial growth. Interestingly, recent studies have shown that
Clostridioides difficile can efficiently use mannotrehalose (2) as
a sole carbon source,21 highlighting the divergence of treha-
lose derivative processing pathways that are available in
different microorganisms. Moreover, 6-azido-trehalose (4) has
previously been found to have very weak antimycobacterial
activities and high minimum inhibitory concentrations (MICs)
of 100–>500 μg mL−1 against Mycobacterium aurum and
Mycobacterium tuberculosis9,22,23 Therefore, we used the resa-
zurin-reduction assay24 to evaluate the ability of mannotreha-
lose (2) and galactotrehalose (3) to inhibit the growth of Mtb in
liquid media and found that compounds 2–3 did not inhibit
the growth of Mtb at concentrations as high as 5 mg mL−1.
Next, we evaluated whether the trehalose analogues 2 and 3
could be taken up by mycobacteria. M. smegmatis was incu-
bated with 100 µM of the corresponding azido-derivatives of
either mannotrehalose (5), galactotrehalose (6) or trehalose (4)
for 4 h. After this time the mycobacteria were pelleted, washed
with PBS containing 0.05% Tween 80 (PBST) to remove any
free sugar and successful labelling was visualised using the
azide-reactive fluorophore, dibenzocyclooctyne-PEG4-tetra-
methylrhodamine (DBCO-PEG4-TAMRA), through strain-pro-
moted copper-free azide–alkyne cycloaddition. In agreement
with previous studies, fluorescence microscopy revealed fluo-
rescent labelling of the mycobacterial cells that had been
treated with azido-trehalose (4).11 Interestingly, we also
observed fluorescent labelling of M. smegmatis cells that had
been treated with azido-mannotrehalose (5) and azido-galacto-
trehalose (6) compared to control mycobacteria cells indicating
that these asymmetric trehalose analogues also label mycobac-
teria. The fluorescent signal from the higher-resolution
Airyscan detector was mostly localised at the cell-surface which
is consistent with the presence of trehalose glycolipids within
the myco-membrane (Fig. 5A). In addition, these results were
Fig. 3 Activity of M. smegmatis TreS with maltose, trehalose (1) and tre-
halose derivatives (2–6). Compounds were incubated with M. smegmatis
TreS enzyme for 0 h or 4.5 h. Mannotrehalose (2), galactotrehalose (3),
azido-trehalose (4), azido-mannotrehalose (5) and azido-galactotreha-
lose (6).
Organic & Biomolecular Chemistry Paper






















































































further corroborated by flow cytometry analysis. Previous
studies have found that azido-trehalose analogues modified at
either the 2- or 6-hydroxyl positions label mycobacteria at low
concentrations (5–25 μM), whereas higher concentrations
(25–500 μM) were required when the azido-group is at either
the 3- or 4-hydroxly position.11 Here, we found that azido-
galactotrehalose (6) was readily incorporated into M. smegmatis
with an efficiency similar to that of azido-trehalose (4), indicat-
ing that an inverted hydroxyl group at the 4-position is also
well tolerated. In contrast, a smaller increase in the number of
cells labelled with azido-mannotrehalose (5) was observed
(Fig. 5). These results suggest that either mycobacteria are
unable to rapidly import the azido-mannotrehalose analogue
(5) with an inverted 2-hydroxyl group or, instead, that 5 cannot
be utilised as efficiently by the mycobacterial biosynthetic pro-
cessing machinery as other azido-containing trehalose deriva-
tives. Azido-trehalose derivatives can be incorporated into the
trehalose mycolates through two pathways: either the disac-
charide is first imported into the cell via the LpqY-SugABC tre-
halose recycling transporter or incorporated into the lipids
using extracellular biosynthetic machinery via the Ag85
complex.6,22 Therefore, to establish the mechanism of incor-
poration of 5 and 6, we repeated these metabolic labelling
experiments in mutant strains of M. smegmatis that lack a func-
tional trehalose transporter.6 Here, we observed that fluo-
rescent labelling of M. smegmatis was almost completely abol-
ished in the presence of the trehalose analogues 4–6 in strains
that lack either the substrate binding domain LpqY or the
nucleotide binding domain SugC of the LpqY-SugABC trans-
porter. Fluorescent labelling was restored in the complemen-
ted strain (Fig. 5B) indicating that in M. smegmatis azido-man-
notrehalose (5) and azido-galactotrehalose (6) are also
imported and incorporated into the trehalose mycolates via
the LpqY-SugABC trehalose recycling pathway.
Finally, to investigate the mycobacterial pathways impacted
in response to the addition of trehalose analogues whole cell
Fig. 4 Growth of Mycobacterium smegmatis and Mycobacterium bovis BCG starved in minimal media and supplemented with either trehalose (1),
mannotrehalose (2) or galactotrehalose (3). A–C: M. smegmatis plus trehalose (A), mannotrehalose (B), galactotrehalose (C). D–F: M. bovis BCG plus
trehalose (D), mannotrehalose (E), galactotrehalose (F). OD595 is optical density at 595 nm. The error bars represent plus/minus SEM of three biologi-
cal replicates are shown in blue.
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proteomics was employed. M. bovis BCG was grown in the pres-
ence of 1.5 mM of either trehalose (1), mannotrehalose (2) or
galactotrehalose (3) for 48 h and the proteins were isolated
using a modified Triton X-114 extraction protocol.25 A list of
all of the proteins identified, annotations and fold changes are
in ESI List 1.† Interestingly, we did not observe any changes in
proteins that are involved in trehalose uptake (LpqY) or metab-
olism (TreS, trehalase) indicating, importantly, that low con-
centrations of trehalose and modified derivatives do not alter
the trehalose biosynthetic machinery of mycobacteria (ESI List
1, Fig. S3†).
Conclusions
In summary, we have taken advantage of the ability to rapidly
access new modified trehalose probes through a single-step
chemoenzymatic route. In combination with bioorthogonal
azide–alkyne click chemistry, we have shown that asymmetric
trehalose derivatives are metabolised by mycobacteria and
incorporated into the mycobacterial cell envelope via the treha-
lose recycling pathway. In direct contrast to trehalose (1), man-
notrehalose (2), galactotrehalose (3) and the corresponding
6-azido analogues (5–6) that retain the α,α1,1-glycosidic
Fig. 5 Labelling of M. smegmatis with azido-trehalose (4), azido-mannotrehalose (5), azido-galactotrehalose (6) and reacted with DBCO-PEG4-
TAMRA. (A) Fluorescence microscopy. Scale bars 5 μm. (B) Flow cytometry analysis.
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linkage are resistant to degradation/isomerisation by mycobac-
terial enzymes. We anticipate that these metabolically stable
probes will be useful tools for the investigation of trehalose
processing in mycobacteria and related microorganisms.
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